| Popis: |
ObjectiveChildhood immune thrombocytopenia (ITP), an acquired bleeding disorder, occurs at any age. Studies have indicated a less favourable prognosis in children aged above ten years. Low lymphocyte counts have been proposed as predictors of chronic disease. Detailed knowledge of ITP disease characteristics and prognosis at various ages may be useful to support clinical decision-making. We aimed to define how age shapes the clinical characteristics, biological parameters and disease outcomes in childhood ITP.DesignPost-hoc analysis of two prospective European studies (NOPHO ITP study and TIKI trial). Children were followed for 6-12 months.SettingPatient inclusion in paediatrics departments in the Netherlands and the five Nordic countries.PatientsChildren aged 9/L).ResultsBy analysing age effects on a continuous scale, we observed that recovery rates at 3-12 months follow-up were gradually reduced in children aged above five years. An absence of a response to IVIg was observed at all ages, but was more common in older children, in particular above 6 years of age. Leukocyte and lymphocyte subset counts were reduced with age, but not elevated or decreased compared to age-appropriate reference intervals. Children aged below seven years showed elevated thrombopoietin levels.ConclusionsAlready from five years of age onwards, there is an increasing risk for a long-lasting course of ITP. Given the varying treatment responses and biological variation, age differences should be considered for the design of clinical trials, prediction models and biological studies. |
